Printer Friendly

Novo Nordisk obtains United States patent.

Novo Nordisk A/S (Bagsvaerd, Denmark) has patented insulin precursors and insulin precursor analogs having a mini C-peptide comprising at least one aromatic amino acid residue have an increased folding stability. The insulin precursors and insulin precursor analogs can be expressed in yeast in high yields and are preferably not more 15 amino acid residues in length. Also provided are polynucleotide sequences encoding the claimed precursors or precursor analogs, and vectors and cell lines containing such polynucleotide sequences. (US 6,521,738)
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:4EUDE
Date:Feb 1, 2003
Previous Article:Phairson Medical obtains United States patent.
Next Article:Scripps Research Institute obtains United States patent.

Related Articles
Aradigm issued new method patent for pulmonary delivery of insulin analogs.
Novo Nordisk and Pharmacia reach out-of-court settlement in human growth hormone.
Novo Nordisk sues Sanofi-Aventis for insulin delivery device patent infringement.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters